---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-264514"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2026-06-10T00:30:15+00:00"
generated_at: "2026-06-10T10:08:02.369036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aldeyra Therapeutics Appoints Darlene Deptula-Hicks as New Director and Audit Committee Chair

## Summary
- Darlene Deptula-Hicks appointed Class III director and Audit Committee Chair on June 9, 2026.
- Ms. Deptula-Hicks received an option to purchase 94,313 shares vesting over three years.
- Annual meeting ratified BDO USA as auditor; advisory say-on-pay passed.
- Todd C. Brady, M.D., Ph.D., re-elected as director with 23,026,101 votes for.

## SEC filing metadata
- accession: 0001193125-26-264514
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2026-06-10T00:30:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/aldx-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-264514
- JSON: https://secwatch.observer/filing/0001193125-26-264514.json
- Plain text: https://secwatch.observer/filing/0001193125-26-264514.txt

## Key facts
- Executive change
  Darlene Deptula-Hicks was appointed as Class III director and Chair of the Audit Committee at Aldeyra Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director and Chair of the Audit Committee
  source text: the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial term expiring at the Company’s 2029 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers (non-binding) at the 2026-06-09 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 3: Advisory Vote on Executive Compensation. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 19,477,504 4,543,221 87,138 20,038,067
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Election of one director to serve as a Class III director at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 1: Election of Directors. The Company’s stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders or until his successor is duly elected and qualified or until earlier death, resignation or removal. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Todd C. Brady, M.D., Ph.D. 23,026,101 1,081,762 20,038,067
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm
- Shareholder Votes
  Aldeyra Therapeutics, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining 43,693,772 321,501 130,657
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/0001193125-26-264514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.